Document is current
Any future updates will be listed below
-
Authors
Meneveau, Max O https://orcid.org/0000-0002-8410-061X
Kumar, Pankaj
Lynch, Kevin T
Patel, Sapna P https://orcid.org/0000-0003-1339-1517
Slingluff, Craig L https://orcid.org/0000-0002-6664-4373
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00705640 at ClinicalTrials.govnct01585350 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
nct02126579 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
340 Cancer vaccination induces high-avidity T cell receptors reactive to endogenously presented target antigens for use in future T cell therapies for HLA-A*03:01 <sup>+</sup> cancer patients
https://doi.org/10.1136/jitc-2025-sitc2025.0340
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
nct02425306 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
https://doi.org/10.1136/jitc-2021-003220
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma
https://doi.org/10.1016/j.cct.2015.01.016
nct00705640 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
nct01585350 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
nct02126579 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
340 Cancer vaccination induces high-avidity T cell receptors reactive to endogenously presented target antigens for use in future T cell therapies for HLA-A*03:01 <sup>+</sup> cancer patients
https://doi.org/10.1136/jitc-2025-sitc2025.0340
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
nct02425306 at ClinicalTrials.govDocuments that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund’s adjuvant (IFA) for resected high-risk melanoma
https://doi.org/10.1136/jitc-2021-003220
A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma
https://doi.org/10.1016/j.cct.2015.01.016
Documents that mention this clinical trial
The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling
https://doi.org/10.1136/jitc-2021-003533
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Incomplete Freund’s adjuvant reduces arginase and enhances Th1 dominance, TLR signaling and CD40 ligand expression in the vaccine site microenvironment
https://doi.org/10.1136/jitc-2020-000544
-
Funding
Funding for this research was provided by:
Cancer Research Institute (CLIP award)
NCI (P30 CA044579)
NCI (R01 CA057653)
NCI (RO1 CA178846)
NCI (T32 CA163177)
NCI (T32HL007849)
Melanoma Research Alliance (210369)
- License Information
